Citius pharmaceuticals, inc. receives regulatory guidance from the u.s. food and drug administration (fda) regarding the planned resubmission of the bla for lymphir™

Resubmission to fda planned for early 2024 cranford, n.j. , sept. 8, 2023 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr) is pleased to announce the company has received additional guidance from the u.s. food and drug administration (fda) regarding the planned resubmission of the company's biologics license application (bla) for lymphir™ (denileukin diftitox), an engineered il-2-diphtheria toxin fusion protein for the treatment of patients with relapsed or refractory cutaneous t-cell lymphoma (ctcl) after at least one prior systemic therapy.
CTXR Ratings Summary
CTXR Quant Ranking